培美曲塞-话题@MedSci

#培美曲塞#

31篇内容 | 2382人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2254896, encodeId=56f72254896a1, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=读书报告 | 培美曲塞维持治疗对转移性非小细胞肺癌患者接受帕博利珠单抗-铂类-培美曲塞诱导治疗结局的影响, objectType=article, longId=865479, objectId=387f8654e9e1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241230/1735552536799_8538692.png, objectUrl=/article/show_article.do?id=387f8654e9e1, replyNumber=0, likeNumber=13, createdTime=2025-03-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=387f8654e9e1, moduleTitle=读书报告 | 培美曲塞维持治疗对转移性非小细胞肺癌患者接受帕博利珠单抗-铂类-培美曲塞诱导治疗结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=387f8654e9e1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175906, encodeId=9f1121e5906cf, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=675e108864ea' target=_blank style='color:#2F92EE;'>#脑转移肺癌#</a>, objectTitle=肺癌脑转、脑膜转后，化疗药培美曲塞能助靶向药奥希替尼一臂之力！, objectType=article, longId=804326, objectId=180580432609, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=180580432609, replyNumber=0, likeNumber=118, createdTime=2023-12-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=180580432609, moduleTitle=肺癌脑转、脑膜转后，化疗药培美曲塞能助靶向药奥希替尼一臂之力！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=180580432609)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1395307, encodeId=6cb8139530e32, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, objectType=article, longId=736047, objectId=95aee36047ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aee36047ae, replyNumber=0, likeNumber=147, createdTime=2022-08-18, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aee36047ae, moduleTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95aee36047ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395306, encodeId=e79e139530621, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=培美曲塞：提前1周 or 同期应用叶酸及VB12？超全用药说明来了, objectType=article, longId=724674, objectId=0adce24674b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0adce24674b3, replyNumber=0, likeNumber=87, createdTime=2022-04-22, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0adce24674b3, moduleTitle=培美曲塞：提前1周 or 同期应用叶酸及VB12？超全用药说明来了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0adce24674b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395305, encodeId=95111395305b2, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=89, createdTime=2021-12-21, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395304, encodeId=e0ea1395304e8, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, objectType=article, longId=221343, objectId=6363221343dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6363221343dc, replyNumber=0, likeNumber=110, createdTime=2021-12-02, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6363221343dc, moduleTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6363221343dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395303, encodeId=b0ca13953034e, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=220916, objectId=e3f82209162c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f82209162c, replyNumber=0, likeNumber=73, createdTime=2021-11-25, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f82209162c, moduleTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3f82209162c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395302, encodeId=cfc9139530231, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=101, createdTime=2021-11-18, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395301, encodeId=1c7313953013e, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=220113, objectId=b4a822011305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a822011305, replyNumber=0, likeNumber=83, createdTime=2021-11-12, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a822011305, moduleTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a822011305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395300, encodeId=61f3139530013, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, objectType=article, longId=219975, objectId=348e2199e529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=348e2199e529, replyNumber=0, likeNumber=78, createdTime=2021-11-10, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=348e2199e529, moduleTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=348e2199e529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395299, encodeId=57171395299a3, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=99, createdTime=2021-10-02, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395298, encodeId=a928139529858, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, objectType=article, longId=217452, objectId=1a0421e45297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0421e45297, replyNumber=0, likeNumber=131, createdTime=2021-09-24, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0421e45297, moduleTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0421e45297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395297, encodeId=6ecc139529ea4, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, objectType=article, longId=215469, objectId=aafc2154691d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aafc2154691d, replyNumber=0, likeNumber=100, createdTime=2021-08-10, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aafc2154691d, moduleTitle=JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aafc2154691d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395296, encodeId=3aeb1395296fb, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=培美曲塞联合免疫抑制剂激素如何使用？, objectType=article, longId=214977, objectId=875d2149e722, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=875d2149e722, replyNumber=0, likeNumber=98, createdTime=2021-07-30, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=875d2149e722, moduleTitle=培美曲塞联合免疫抑制剂激素如何使用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=875d2149e722)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395295, encodeId=f3641395295a1, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, objectType=article, longId=214414, objectId=2f7c2144147c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7c2144147c, replyNumber=0, likeNumber=102, createdTime=2021-07-21, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7c2144147c, moduleTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f7c2144147c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395294, encodeId=eeab13952943b, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=68, createdTime=2021-06-17, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395293, encodeId=12051395293a0, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), objectType=article, longId=199903, objectId=f051199903bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f051199903bb, replyNumber=0, likeNumber=101, createdTime=2020-08-26, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f051199903bb, moduleTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f051199903bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395292, encodeId=c2e91395292d1, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Clin Cancer Res：Ganetespib联合培美曲塞+铂类治疗恶性胸膜间皮瘤, objectType=article, longId=198667, objectId=2f6b19866e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6b19866e72, replyNumber=0, likeNumber=152, createdTime=2020-08-05, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6b19866e72, moduleTitle=Clin Cancer Res：Ganetespib联合培美曲塞+铂类治疗恶性胸膜间皮瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6b19866e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395291, encodeId=ec85139529140, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, objectType=article, longId=198499, objectId=8e7819849955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7819849955, replyNumber=0, likeNumber=78, createdTime=2020-08-02, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7819849955, moduleTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e7819849955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1395290, encodeId=6796139529030, content=<a href='/topic/show?id=0e7041632f3' target=_blank style='color:#2F92EE;'>#培美曲塞#</a>, objectTitle=Lancet oncol：派姆单抗联合培美曲塞-铂类治疗非鳞状非小细胞肺癌的患者自评预后, objectType=article, longId=187873, objectId=612818e8732b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=612818e8732b, replyNumber=0, likeNumber=0, createdTime=2020-02-13, rootId=0, userName=12498dabm77暂无昵称, userId=78c32500188, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=612818e8732b, moduleTitle=Lancet oncol：派姆单抗联合培美曲塞-铂类治疗非鳞状非小细胞肺癌的患者自评预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=612818e8732b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

培美曲塞

2020-05-29

梅斯管理员

#非小细胞肺癌# #培美曲塞#

读书报告 | 培美曲塞维持治疗对转移性非小细胞肺癌患者接受帕博利珠单抗-铂类-培美曲塞诱导治疗结局的影响

2025-03-06发表于陕西省

梅斯管理员

#肺癌# #培美曲塞# #奥希替尼# #脑转移肺癌#

肺癌脑转、脑膜转后，化疗药培美曲塞能助靶向药奥希替尼一臂之力！

2023-12-19发表于上海

12498dabm77暂无昵称

#培美曲塞#

J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌

2022-08-18

12498dabm77暂无昵称

#培美曲塞#

培美曲塞：提前1周 or 同期应用叶酸及VB12？超全用药说明来了

2022-04-22

12498dabm77暂无昵称

#培美曲塞#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2021-12-21

12498dabm77暂无昵称

#培美曲塞#

Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性

2021-12-02

12498dabm77暂无昵称

#培美曲塞#

Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌

2021-11-25

12498dabm77暂无昵称

#培美曲塞#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2021-11-18

12498dabm77暂无昵称

#培美曲塞#

Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌

2021-11-12

12498dabm77暂无昵称

#培美曲塞#

Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性

2021-11-10

12498dabm77暂无昵称

#培美曲塞#

Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比

2021-10-02

12498dabm77暂无昵称

#培美曲塞#

ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性

2021-09-24

12498dabm77暂无昵称

#培美曲塞#

JTO:信迪利单抗（Sintilimab）联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新： 3期临床研究（ORIENT-11）。

2021-08-10

12498dabm77暂无昵称

#培美曲塞#

培美曲塞联合免疫抑制剂激素如何使用？

2021-07-30

12498dabm77暂无昵称

#培美曲塞#

J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性

2021-07-21

12498dabm77暂无昵称

#培美曲塞#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2021-06-17

12498dabm77暂无昵称

#培美曲塞#

JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11)

2020-08-26

12498dabm77暂无昵称

#培美曲塞#

Clin Cancer Res：Ganetespib联合培美曲塞+铂类治疗恶性胸膜间皮瘤

2020-08-05

12498dabm77暂无昵称

#培美曲塞#

J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析

2020-08-02

12498dabm77暂无昵称

#培美曲塞#

Lancet oncol：派姆单抗联合培美曲塞-铂类治疗非鳞状非小细胞肺癌的患者自评预后

2020-02-13

科室
- - 订阅+
  - 更多科室
工具
服务